Structure Therapeutics Inc. has evolved from a “dark horse” to a leading contender in the oral GLP-1 obesity drug market. GPCR’s market cap surged from $1.3B to $5B in five months, reflecting ...
After Novo Nordisk A/S' (NYSE: NVO) launch of the first oral GLP-1 weight-loss drug, the spotlight at the JPMorgan Healthcare Conference turned sharply toward obesity treatments and what comes next ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results